DenovAI Biotech Revenue
Biotechnology Research • 
Rehovot, Center District, Israel • 11-20 Employees
DenovAI Biotech revenue & valuation
| Annual revenue | $941,105 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,100,000 |
| Total funding | No funding |
Key Contacts at DenovAI Biotech
Shiri Netser
Member Board Of Directors
Kashif Sadiq
Founder & Ceo
Company overview
| Headquarters | AION Labs, 4 Oppenheimer, Rehovot, 7670104, IL |
| Phone number | +9727670104 |
| Website | |
| NAICS | 541714 |
| Keywords | Drug Development, Drug Discovery, Biologics, Machine Learning, Antibodies, Biotech, Protein Engineering, Discovery Engine, Techbio, Protein Design, De Novo, Computational Biophysics, Gen-Ai, Bio-Convergence, Bioconve, Mini Proteins |
| Founded | 2023 |
| Employees | 11-20 |
| Socials |
DenovAI Biotech Email Formats
DenovAI Biotech uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@denovai.com), used 55.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@denovai.com | 55.6% |
{first initial} | j@denovai.com | 22.2% |
{first initial}.{last name} | j.doe@denovai.com | 22.2% |
About DenovAI Biotech
At DenovAI Biotech we are re-imagining the future of therapeutic protein design - we believe that humanity is in the midst of a protein design revolution that stands to transform human health and the world around us. Our vision is to revolutionize biologics discovery with our proprietary Gen AI and molecular biophysics platform for the de-novo design of therapeutic proteins, totally from scratch. Focusing on next generation therapeutic antibodies and miniproteins, our vision is to accelerate the pace of biologics discovery from years to weeks, dramatically lower the cost of preclinical development and reduce the high failure rate of drug development - by designing the right molecule, right from the start! DenovAI has been created as a portfolio company of the AION Labs venture studio (https://aionlabs.com), through the investment of leading pharmaceutical companies Pfizer, AstraZeneca, Merck, and Teva, with close support from Amazon Web Services (AWS) and additional financial backing from the Israel Innovation Authority, the Israel Biotech Fund and Amiti Ventures.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
DenovAI Biotech has 6 employees across 4 departments.
Departments
Number of employees
Funding Data
DenovAI Biotech has never raised funding before.
DenovAI Biotech Tech Stack
Discover the technologies and tools that power DenovAI Biotech's digital infrastructure, from frameworks to analytics platforms.
Hosting
CMS
Miscellaneous
Security
JavaScript frameworks
JavaScript frameworks
Miscellaneous
India
United States
Belgium
Finland
Frequently asked questions
4.8
40,000 users
